论文部分内容阅读
目的 观察抗肿瘤药物丝裂霉素（ ＭＭＣ）、西艾克（ＶＤＳ）和顺铂（ ＤＤＰ）组成的 ＭＶＰ方案治疗晚期非小细胞肺癌（ＮＳＣＬＣ）的近期疗效和毒性。方法 治疗老年晚期非小细胞肺癌 ５６例，用 ＭＶＰ方案：ＭＭＣ ６ｍｇ／ｍ～２静推第１天，ＶＤＳ ３ｍｇ／ｍ～２静推第１、８天，ＤＤＰ ４０ｍｇ静滴第１～３天。结果该方案近期有效率４６．４％，毒性反应主要为骨髓抑制，Ⅲ、Ⅳ度白细胞下降率３９％，Ⅲ、Ⅳ度血小板下降率１６％，Ⅲ、Ⅳ度恶心呕吐发生率２１％。结论 ＭＭＣ、ＶＤＳ、ＤＤＰ联合治疗非小细胞肺癌有效率高，其毒性患者可以耐受，是临床治疗非小细胞肺癌切实可行的方案。
Objective To observe the short-term efficacy and toxicity of antitumor drugs MMC, VDS and DDP in the treatment of advanced non-small cell lung cancer (NSCLC). Methods 56 patients with advanced advanced non-small cell lung cancer were treated with MVP regimen: MMC 6 mg/m~2 statically pushed for 1 day, VDS 3 mg/m~2 statically pushed for 1st and 8th days, DDP 40 mg intravenously for 1~3 days . Results The efficiency of this regimen was 46.4% in the near future. The toxicity was mainly myelosuppression. The rate of leukopenia was 39% in grades III and IV. The platelet decrease rate was 16% in grades III and IV. The incidence of nausea and vomiting in grades III and IV was 21%. Conclusion The combination of MMC, VDS and DDP is effective in the treatment of non-small cell lung cancer. The toxicity of the combination of MMC, VDS and DDP can be tolerated. It is a practical and feasible solution for the treatment of non-small cell lung cancer.